Cyclopharm (CYC.AX) Stock Price
Cyclopharm Price
Revenue has compounded at 6.2% per year over the past 19 years to 32.33 M AUD. Earnings per share have declined at 14.1% per year over the last 10 years. Cyclopharm's net margin stands at -53.3%, down from -28.5% several years earlier. Cyclopharm currently offers a dividend yield of about 2.25%. The dividend has grown at 4.4% per year over the past 8 years. Analysts set a median price target of 1.53 AUD, implying 243.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Cyclopharm stock price
Cyclopharm business model & stock analysis
Frequently asked questions about Cyclopharm
The business model of Cyclopharm Ltd revolves around the development and commercialization of nuclear medicine products. Cyclopharm is a global leader in the manufacture and distribution of Technegas, a diagnostic imaging agent used for the detection of pulmonary embolism. With a focus on nuclear medicine, Cyclopharm carries out research, development, and production activities to offer innovative solutions for physicians and patients in need of accurate diagnoses. By leveraging their expertise in nuclear medicine, Cyclopharm aims to improve medical imaging techniques and contribute to better patient outcomes worldwide.
Cyclopharm Ltd is primarily active in the medical and healthcare industries.
The main competitors of Cyclopharm Ltd in the market include Progenics Pharmaceuticals, Curium, and Navidea Biopharmaceuticals. These companies also operate in the medical imaging industry and offer products and services that compete with Cyclopharm's offerings.
Cyclopharm Ltd is a leading global radiopharmaceutical company. Established in 1988, Cyclopharm focuses on developing and commercializing innovative nuclear medicine products. The company specializes in technetium generators, used for diagnostic imaging procedures, particularly in lung ventilation and perfusion examinations. With a strong commitment to research and development, Cyclopharm has continued to expand its product portfolio and global presence over the years. The company is headquartered in Sydney, Australia, and has a strong track record in delivering advanced solutions for the medical imaging industry. Cyclopharm Ltd has emerged as a trusted name in the field of radiopharmaceuticals, providing cutting-edge diagnostic tools for better patient care.
Cyclopharm Ltd, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and launched innovative nuclear medicine technologies, including Technegas, a ventilation imaging agent rapidly adopted by the global medical community. Cyclopharm Ltd has established a strong international presence, with distribution networks spanning across multiple continents, allowing them to provide their life-saving products to patients worldwide. The company's commitment to research and development has yielded groundbreaking advancements in diagnostic imaging, revolutionizing the industry. Cyclopharm Ltd continues to strive for excellence, consistently delivering cutting-edge solutions and improving patient outcomes.
Cyclopharm Ltd is primarily present in Australia, New Zealand, and Canada.
Cyclopharm Ltd represents values of innovation, excellence, and patient care. The company maintains a strong corporate philosophy centered around enhancing the field of nuclear medicine through advanced radiopharmaceutical products and services. Cyclopharm Ltd is committed to delivering reliable diagnostic solutions that enable healthcare professionals to effectively diagnose and monitor various diseases. With a focus on research and development, the company strives to introduce groundbreaking technologies and therapies to improve patient outcomes. As a leader in the nuclear medicine industry, Cyclopharm Ltd continuously aims to provide cutting-edge solutions that contribute to the advancement of medical imaging and patient well-being.
Analysts currently set an average price target of 1.53 AUD for the Cyclopharm stock (median: 1.53 AUD), implying +243.8 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Cyclopharm stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cyclopharm to generate revenue of 37.20 M AUD and earnings per share of -0.13 AUD.
Converted at the current exchange rate, the Cyclopharm share trades at 0.27 EUR (0.45 AUD).
Cyclopharm Ltd is an Australian medical technology company specializing in X-ray diagnostics. The company offers innovative diagnostic solutions and services for nuclear medicine imaging and therapy planning. The company's main business model focuses on three different divisions: diagnostics, therapy planning, and research. Each division has its own products and services. For diagnostics, Cyclopharm offers Atomlab® Systems, a platform for nuclear medicine imaging that combines PET and SPECT technology. Atomlab® Systems facilitates radiologists and doctors in making critical decisions by providing detailed images of the body to help detect abnormalities and diseases. For therapy planning, Cyclopharm offers Technegas®, a technology that allows for checking lung function and perfusion to support the diagnosis of diseases such as pulmonary embolism. Technegas® is approved by the European Union and the US Food and Drug Administration (FDA) and is considered an important part of clinical practice. In addition, Cyclopharm offers a comprehensive portfolio of radioactive isotopes used in diagnostics and therapy planning. Cyclopharm's research division focuses on developing new diagnostic methods and technologies to improve nuclear medicine imaging and deliver better outcomes for patients. The company collaborates with leading academic institutions and research facilities worldwide to develop innovative diagnostic and treatment options. Cyclopharm is headquartered in Sydney, Australia, and distributes its products and services globally. The company employs approximately 100 employees and is listed on the Australian stock exchange. Cyclopharm's business model is based on offering innovative and high-quality diagnostic solutions tailored to the needs of radiologists, doctors, and patients. By combining PET and SPECT technology, Technegas technology, and an isotope portfolio, Cyclopharm has a unique position in nuclear medicine imaging. The company is also committed to sustainability and strives for environmental compatibility and safety in all aspects of its products and services. It works closely with regulatory authorities to ensure compliance with all relevant regulations and guidelines. Overall, Cyclopharm is a leading provider of diagnostic solutions and services in nuclear medicine imaging. Through innovative technology and a strong focus on research and development, the company will continue to play an important role in the industry and contribute to improving healthcare worldwide.
The expected revenue of Cyclopharm is 37.20 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cyclopharm is -14.20 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cyclopharm is currently -3.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cyclopharm stock.
The price-to-sales ratio (P/S) of Cyclopharm is currently 1.32. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cyclopharm stock.
The Eulerpool Quality Score for Cyclopharm is 3/10.
The ISIN of Cyclopharm is AU000000CYC5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Cyclopharm is CYC.AX. The ticker symbol is used to trade Cyclopharm shares on the stock exchange.
Cyclopharm stock
Cyclopharm Peer Group
Cyclopharm FIGI
All fundamentals and in-depth analysis of Cyclopharm
Our stock analysis for Cyclopharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.